Open AccessImpaired glucose tolerance, body mass index and respiratory function in patients with cystic fibrosis: A systematic review
Author(s) -
Iwanicki Courtney,
Logomarsino John V.
Publication year - 2019
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.13019
Subject(s) - medicine , cystic fibrosis , body mass index , impaired glucose tolerance , respiratory system , obesity , insulin resistance
Objectives This systematic review aims to evaluate body mass index (BMI) and forced expiratory volume in one second (FEV 1 ) in patients with cystic fibrosis (CF) diagnosed with impaired glucose tolerance (IGT) compared to those with normal glucose tolerance (NGT). The significance of this topic stems from concern that individuals with CF and IGT may have an overall worse clinical status as indicated by BMI and FEV 1 . Data Source An exhaustive literature search was completed between July 2017 and September 2017 using PubMed, CINAHL, Web of Science, Dissertations & Theses, PsycINFO, and Open Grey. Studies were limited to human subjects with CF. There were no restrictions on publication date, study design or language. Study Selection Included studies examined BMI and FEV 1 as outcome measures in individuals with CF and IGT compared to those with NGT. After screening for inclusion criteria, 12 observational studies met the specified conditions. Results Two studies showed a significantly worse BMI and FEV 1 in subjects with CF and IGT compared to those with NGT. The remaining 10 studies found no significant associations with BMI and FEV 1 in subjects with CF and IGT compared to NGT. Conclusion Although this review does not prove cause and effect, BMI and FEV 1 are important outcome measures in patients with CF. Considering the inconclusive findings, practitioners should individualize care for this patient population. Additional research should focus on clinical status and interventions/treatment for individuals with CF and IGT.